Unknown

Dataset Information

0

Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.


ABSTRACT: Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable AmpC beta-lactamases, and carbapenemases are associated with laboratory testing problems of false susceptibility that can lead to inappropriate therapy for infected patients. Because there appears to be a lack of awareness of these enzymes, a study was conducted during 2001 to 2002 in which 6,421 consecutive, nonduplicate clinical isolates of aerobically growing gram-negative bacilli from patients at 42 intensive care unit (ICU) and 21 non-ICU sites across the United States were tested on-site for antibiotic susceptibility. From these isolates, 746 screen-positive isolates (11.6%) were referred to a research facility and investigated to determine the prevalence of ESBLs in all gram-negative isolates, transferable AmpC beta-lactamases in Klebsiella pneumoniae, and carbapenemases in Enterobacteriaceae. The investigations involved phenotypic tests, isoelectric focusing, beta-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular analyses. ESBLs were detected only in Enterobacteriaceae (4.9% of all Enterobacteriaceae) and were found in species other than those currently recommended for ESBL testing by the CLSI (formerly NCCLS). These isolates occurred at 74% of the ICU sites and 43% of the non-ICU sites. Transferable AmpC beta-lactamases were detected in 3.3% of K. pneumoniae isolates and at 16 of the 63 sites (25%) with no difference between ICU and non-ICU sites. Three sites submitted isolates that produced class A carbapenemases. No class B or D carbapenemases were detected. In conclusion, organisms producing ESBLs and transferable AmpC beta-lactamases were widespread. Clinical laboratories must be able to detect important beta-lactamases to ensure optimal patient care and infection control.

SUBMITTER: Moland ES 

PROVIDER: S-EPMC1594717 | biostudies-literature | 2006 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.

Moland Ellen S ES   Hanson Nancy D ND   Black Jennifer A JA   Hossain Ashfaque A   Song Wonkeun W   Thomson Kenneth S KS  

Journal of clinical microbiology 20060901 9


Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable AmpC beta-lactamases, and carbapenemases are associated with laboratory testing problems of false susceptibility that can lead to inappropriate therapy for infected patients. Because there appears to be a lack of awareness of these enzymes, a study was conducted during 2001 to 2002 in which 6,421 consecutive, nonduplicate clinical isolates of aerobically growing gram-negative bacilli from patients at 42 intensi  ...[more]

Similar Datasets

| S-EPMC2585144 | biostudies-literature
| S-EPMC6325186 | biostudies-literature
| S-EPMC5652419 | biostudies-literature
| S-EPMC4803319 | biostudies-literature
| S-EPMC8386808 | biostudies-literature
| S-EPMC132764 | biostudies-literature
| S-EPMC7936229 | biostudies-literature
| PRJNA805242 | ENA
| S-EPMC7927846 | biostudies-literature
| S-EPMC9793173 | biostudies-literature